Anika Therapeutics, Inc. — Q1 2016 Form 10-Q Summary
Business context and reporting period
Anika Therapeutics is a global orthopedic medicines company developing, manufacturing, and commercializing hyaluronic-acid-based products across orthobiologics, surgical, dermal, ophthalmic, and veterinary markets. The filing covers the unaudited three months ended March 31, 2016, compared with the same period in 2015.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Total revenue | $22.3 million | $15.5 million | +44% |
| Product revenue | $22.3 million | $15.5 million | +44% |
| Gross profit on products | $16.9 million | $11.2 million | +50% |
| Product gross margin | 76% | 72% | +4 percentage points |
| Income from operations | $10.7 million | $5.5 million | +95% |
| Net income | $6.9 million | $3.5 million | +96% |
| Diluted EPS | $0.45 | $0.23 | +$0.22 |
| Cash flow from operations | $7.7 million | $4.0 million | +93% |
- Operating margin was approximately 48% versus 35% in the prior-year quarter; net margin was approximately 31% versus 23%.
- Orthobiologics revenue increased 64% to $19.6 million and represented the principal growth driver. Surgical revenue declined 5%, dermal revenue declined 8%, and other revenue declined 43%.
- United States revenue was $18.0 million, or 81% of total revenue; Europe contributed $2.6 million, or 11%; and other regions contributed $1.7 million, or 8%.
- Cash and cash equivalents were $92.8 million at March 31, 2016, compared with $110.7 million at December 31, 2015. Investments were $23.0 million, resulting in cash, cash equivalents, and investments of approximately $115.8 million.
- Working capital was approximately $137.0 million, compared with $159.2 million at year-end 2015. The filing does not identify outstanding debt; reported liabilities were primarily operating, tax, deferred-tax, and lease-related obligations.
- Capital expenditures were $6.4 million, primarily related to expanded Bedford, Massachusetts manufacturing capabilities. Financing cash outflows included a $25.0 million accelerated share repurchase.
Material changes versus the prior comparable period
- Revenue growth reflected stronger orthobiologics demand and approximately $5.8 million of additional sales to the company’s U.S. commercial partner. The prior-year comparison was affected by that partner’s multi-month inventory reset.
- Improved product mix, particularly higher-margin orthobiologics products, increased product gross margin from 72% to 76%.
- Research and development expense increased 3% to $2.2 million, while selling, general, and administrative expense increased 11% to $4.0 million.
- Cash from operations increased to $7.7 million, helped by higher net income and a $7.0 million reduction in accounts receivable.
- The company repurchased $25.0 million of common stock under an accelerated share repurchase agreement, initially receiving 377,155 shares. Approximately $7.5 million remained under the agreement at March 31, 2016, with final settlement expected in or before the third quarter of 2016.
- Foreign currency translation produced a $0.8 million comprehensive-income benefit in Q1 2016, compared with a $2.2 million loss in Q1 2015.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects orthobiologics revenue to continue growing in 2016, supported by MONOVISC in the United States, planned CINGAL launches in Canada and Europe, and broader viscosupplementation demand.
- Management expects moderate full-year declines in surgical revenue because of inventory releveling by a U.S. ENT commercial partner, and lower other revenue primarily due to lower veterinary revenue. Advanced wound-care revenue is expected to increase.
- CINGAL received CE Mark approval in March 2016, and initial commercial sales in Canada and the European Union were expected in Q2 2016. U.S. regulatory discussions indicated that additional clinical work may be required before an NDA pathway is finalized.
- HYALOFAST entered an early-stage Phase III clinical trial after patient enrollment began in December 2015. Research and development spending is expected to increase in 2016 and thereafter.
- The company expects to spend approximately $15 million through 2018 on moving HYAFF-based manufacturing from Italy to Bedford, including approximately $8.0 million over the following 12 to 15 months after March 31, 2016.
- Anika expects adequate financial resources to support operations for at least the next twelve months. Management states that additional financing could be required if operating cash flow and existing resources become insufficient, but no such need is currently indicated.
- A new European headquarters facility in Padova, Italy is expected to be completed in late 2016, with a 15-year lease and initial annual rent of approximately $0.4 million. Construction-in-process and a related lease obligation were recorded at March 31, 2016.
- Normal-course legal proceedings are not expected to have a material adverse effect. The filing reports no material changes to previously disclosed risk factors, market risks, or internal controls.
Important facts for investors to verify
- Whether the Q1 orthobiologics growth is sustained after the prior-year distributor inventory reset effect normalizes.
- The timing and commercial uptake of CINGAL in Canada and Europe and the additional clinical and regulatory requirements for U.S. approval.
- The final share count and cash or share settlement under the $25.0 million accelerated share repurchase agreement.
- The remaining cost, timing, and execution risks associated with the Bedford manufacturing expansion and the Padova facility.
- The impact of future product mix, distributor ordering patterns, foreign exchange, and rising research and development and SG&A spending on margins and cash flow.
- The filing’s statement that reported first-quarter results are not necessarily indicative of full-year 2016 results.